Future Treatment of Neuropathic Pain in Spinal Cord Injury: The Challenges of Nanomedicine, Supplements or Opportunities?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Jun 24

PMID 35740395

Authors

Giuseppe Forte

Valentina Giuffrida

Angelica Scuderi

Mariella Pazzaglia

Affiliations

Soon will be listed here.

Abstract

Neuropathic pain (NP) is a common chronic condition that severely affects patients with spinal cord injuries (SCI). It impairs the overall quality of life and is considered difficult to treat. Currently, clinical management of NP is often limited to drug therapy, primarily with opioid analgesics that have limited therapeutic efficacy. The persistence and intractability of NP following SCI and the potential health risks associated with opioids necessitate improved treatment approaches. Nanomedicine has gained increasing attention in recent years for its potential to improve therapeutic efficacy while minimizing toxicity by providing sensitive and targeted treatments that overcome the limitations of conventional pain medications. The current perspective begins with a brief discussion of the pathophysiological mechanisms underlying NP and the current pain treatment for SCI. We discuss the most frequently used nanomaterials in pain diagnosis and treatment as well as recent and ongoing efforts to effectively treat pain by proactively mediating pain signals following SCI. Although nanomedicine is a rapidly growing field, its application to NP in SCI is still limited. Therefore, additional work is required to improve the current treatment of NP following SCI.

Citing Articles

Unveiling the effects of oligosaccharide liposome on neuropathic pain and motor dysfunction following spinal cord injury in rats: relevance to its antioxidative effects.

Ahmadpour Y, Bahrami G, Arkan E, Abbaszadeh F, Aghaz F, Fakhri S Front Pharmacol. 2025; 16:1533025.

PMID: 40028155 PMC: 11868053. DOI: 10.3389/fphar.2025.1533025.

The Therapeutic Potential of MicroRNA-21 in the Treatment of Spinal Cord Injury.

Hasan A, Ardizzone A, Giosa D, Scuderi S, Calcaterra E, Esposito E Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996791 PMC: 11854632. DOI: 10.3390/cimb47020070.

Comparative outcomes of microsurgical dorsal root entry zone lesioning (DREZotomy) for intractable neuropathic pain in spinal cord and cauda equina injuries.

Sitthinamsuwan B, Ounahachok T, Pumseenil S, Nunta-Aree S Neurosurg Rev. 2025; 48(1):17.

PMID: 39747752 PMC: 11695575. DOI: 10.1007/s10143-024-03136-y.

To Be in Pain: Pain Multidimensional Questionnaire as Reliable Tool to Evaluate Multifaceted Aspects of Pain.

Forte G, Favieri F, De Pascalis V, Casagrande M J Clin Med. 2024; 13(19).

PMID: 39407946 PMC: 11477689. DOI: 10.3390/jcm13195886.

A cutting-edge new framework for the pain management in children: nanotechnology.

Starcea I, Lupu A, Nistor A, Mocanu M, Bogos R, Azoicai A Front Mol Neurosci. 2024; 17:1391092.

PMID: 39318422 PMC: 11420925. DOI: 10.3389/fnmol.2024.1391092.

References

Zantedeschi M, Pazzaglia M . Commentary: Non-invasive Brain Stimulation, a Tool to Revert Maladaptive Plasticity in Neuropathic Pain. Front Hum Neurosci. 2016; 10:544. PMC: 5081357. DOI: 10.3389/fnhum.2016.00544. View

Lalani J, Patil S, Kolate A, Lalani R, Misra A . Protein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management. AAPS PharmSciTech. 2014; 16(2):413-27. PMC: 4370975. DOI: 10.1208/s12249-014-0235-3. View

Feng J, Lepetre-Mouelhi S, Gautier A, Mura S, Cailleau C, Coudore F . A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine. Sci Adv. 2019; 5(2):eaau5148. PMC: 6374102. DOI: 10.1126/sciadv.aau5148. View

Gwak Y, Kang J, Unabia G, Hulsebosch C . Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol. 2011; 234(2):362-72. PMC: 3303938. DOI: 10.1016/j.expneurol.2011.10.010. View

Oladosu F, Maixner W, Nackley A . Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management. Mayo Clin Proc. 2015; 90(8):1135-51. PMC: 5024555. DOI: 10.1016/j.mayocp.2015.06.010. View

Yaksh T, Provencher J, RATHBUN M, Kohn F . Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. Anesthesiology. 1999; 90(5):1402-12. DOI: 10.1097/00000542-199905000-00025. View

Gwak Y, Hulsebosch C . GABA and central neuropathic pain following spinal cord injury. Neuropharmacology. 2011; 60(5):799-808. PMC: 3285561. DOI: 10.1016/j.neuropharm.2010.12.030. View

Nakatani Y, Masuko H, Amano T . Effect of lamotrigine on Na(v)1.4 voltage-gated sodium channels. J Pharmacol Sci. 2013; 123(2):203-6. DOI: 10.1254/jphs.13116sc. View

Sindrup S, Jensen T . Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999; 83(3):389-400. DOI: 10.1016/S0304-3959(99)00154-2. View

10.

Gustin S, Peck C, Cheney L, Macey P, Murray G, Henderson L . Pain and plasticity: is chronic pain always associated with somatosensory cortex activity and reorganization?. J Neurosci. 2012; 32(43):14874-84. PMC: 6704842. DOI: 10.1523/JNEUROSCI.1733-12.2012. View

11.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

12.

Lee S, Zhao X, Hatch M, Chun S, Chang E . Central Neuropathic Pain in Spinal Cord Injury. Crit Rev Phys Rehabil Med. 2015; 25(3-4):159-172. PMC: 4350234. DOI: 10.1615/CritRevPhysRehabilMed.2013007944. View

13.

Latremoliere A, Woolf C . Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10(9):895-926. PMC: 2750819. DOI: 10.1016/j.jpain.2009.06.012. View

14.

Beric A . Post-spinal cord injury pain states. Pain. 1997; 72(3):295-8. View

15.

Boucher T, McMahon S . Neurotrophic factors and neuropathic pain. Curr Opin Pharmacol. 2001; 1(1):66-72. DOI: 10.1016/s1471-4892(01)00010-8. View

16.

Alyautdin R, Petrov V, Langer K, Berthold A, Kharkevich D, Kreuter J . Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997; 14(3):325-8. DOI: 10.1023/a:1012098005098. View

17.

Ling H, Chen Z, He L, Feng F, Weng C, Cheng S . Comparative Efficacy and Safety of 11 Drugs as Therapies for Adults With Neuropathic Pain After Spinal Cord Injury: A Bayesian Network Analysis Based on 20 Randomized Controlled Trials. Front Neurol. 2022; 13:818522. PMC: 8977449. DOI: 10.3389/fneur.2022.818522. View

18.

Woolf C, Mannion R . Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999; 353(9168):1959-64. DOI: 10.1016/S0140-6736(99)01307-0. View

19.

Longo M, Iannetti G, Mancini F, Driver J, Haggard P . Linking pain and the body: neural correlates of visually induced analgesia. J Neurosci. 2012; 32(8):2601-7. PMC: 6621879. DOI: 10.1523/JNEUROSCI.4031-11.2012. View

20.

Pazzaglia M, Molinari M . The re-embodiment of bodies, tools, and worlds after spinal cord injury: An intricate picture: Reply to comments on "The embodiment of assistive devices-From wheelchair to exoskeleton". Phys Life Rev. 2016; 16:191-4. DOI: 10.1016/j.plrev.2016.02.004. View